{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05761301",
            "orgStudyIdInfo": {
                "id": "ALN-KHK-001"
            },
            "organization": {
                "fullName": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM",
            "officialTitle": "A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-Part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-KHK in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-KHK in Obese Patients With Type 2 Diabetes Mellitus (T2DM)",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "a-phase-study-to-evaluate-aln-khk-in-overweight-to-obese-healthy-volunteers-and-obese-patients-with"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-24",
            "studyFirstSubmitQcDate": "2023-03-07",
            "studyFirstPostDateStruct": {
                "date": "2023-03-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK."
        },
        "conditionsModule": {
            "conditions": [
                "Type 2 Diabetes Mellitus (T2DM)"
            ],
            "keywords": [
                "Overweight",
                "Obese",
                "Fructose",
                "siRNA",
                "HbA1C",
                "Insulin",
                "Glucose"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The single ascending dose part of this study (Part A) will have a sequential interventional study model. The multi-dose part of this study (Part B) will have a parallel interventional study model and will begin after the completion of Part A.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 160,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: ALN-KHK",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered a single dose of ALN-KHK.",
                    "interventionNames": [
                        "Drug: ALN-KHK"
                    ]
                },
                {
                    "label": "Part A: Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will be administered a single dose of placebo.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Part B: ALN-KHK",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered a multiple doses of ALN-KHK.",
                    "interventionNames": [
                        "Drug: ALN-KHK"
                    ]
                },
                {
                    "label": "Part B: Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will be administered a multiple doses of placebo.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ALN-KHK",
                    "description": "ALN-KHK will be administered by subcutaneous (SC) injection.",
                    "armGroupLabels": [
                        "Part A: ALN-KHK",
                        "Part B: ALN-KHK"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will be administered by subcutaneous (SC) injection.",
                    "armGroupLabels": [
                        "Part A: Placebo",
                        "Part B: Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Frequency of Adverse Events",
                    "timeFrame": "Up to 9 Months"
                },
                {
                    "measure": "Part B: Frequency of Adverse Events",
                    "timeFrame": "Up to 12 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A: Area Under the Concentration-time Curve (AUC) of ALN-KHK and Potential Major Metabolite(s)",
                    "timeFrame": "Up to 2 Days following dosing on Day 1"
                },
                {
                    "measure": "Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-KHK and Potential Major Metabolite(s)",
                    "timeFrame": "Up to 2 Days following dosing on Day 1"
                },
                {
                    "measure": "Part A: Time to Maximum Observed Plasma Concentration (Tmax) of ALN-KHK and Potential Major Metabolite(s)",
                    "timeFrame": "Up to 2 Days following dosing on Day 1"
                },
                {
                    "measure": "Part A: Fraction of ALN-KHK Excreted in the Urine (fe) and Potential Major Metabolite(s)",
                    "timeFrame": "Postdose on Day 1"
                },
                {
                    "measure": "Part A: Percent Change from Baseline in Circulating Fructose in Response to a Fructose Tolerance Test",
                    "timeFrame": "Baseline up to Month 6"
                },
                {
                    "measure": "Part A: Percent Change from Baseline in Urinary Fructose in Response to a Fructose Tolerance Test",
                    "timeFrame": "Baseline up to Month 6"
                },
                {
                    "measure": "Part A: Percent Change from Baseline in Circulating Fibroblast Growth Factor 21 (FGF21) in Response to a Fructose Tolerance Test",
                    "timeFrame": "Baseline up to Month 6"
                },
                {
                    "measure": "Part B: Absolute Change from Baseline in Hemoglobin A1C (HbA1c) at 6 Months",
                    "timeFrame": "Baseline and Month 6"
                },
                {
                    "measure": "Parts A and B: Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in Response to a Glucose Tolerance Test",
                    "timeFrame": "Part A: Screening up to Month 3; Part B: Month 4"
                },
                {
                    "measure": "Part B: Fasting Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
                    "timeFrame": "Month 4"
                },
                {
                    "measure": "Parts A and B: Glucose and Insulin AUC in response to Tolerance Test",
                    "timeFrame": "Part A: Screening up to Month 3; Part B: Month 4"
                },
                {
                    "measure": "Part B: Plasma Concentrations of ALN-KHK and Potential Major Metabolite(s)",
                    "timeFrame": "Day 1 and Month 3"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Stable euthyroid status (no known changes in thyroid function; stable hormone replacement for at least 4 months) at screening\n* Part A: body mass index (BMI) \u226527 kg/m\\^2 and \u226434.9 kg/m\\^2\n* Part B: BMI \u226530 kg/m\\^2 to \u226439.9 kg/m\\^2, confirmed diagnosis of T2DM, and an HbA1c \u22657.5% to \\<10%\n* Part B: Confirmed T2DM diagnosis\n\nExclusion Criteria:\n\n* Parts A and B: has received an investigational agent within the last 30 days\n* Part A: History of Type 1 or Type 2 diabetes\n* Part B: History of Type 1 diabetes",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-ALNYLAM",
                    "email": "clinicaltrials@alnylam.com"
                },
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-256-9526",
                    "email": "clinicaltrials@alnylam.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Alnylam Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Lake Worth",
                    "state": "Florida",
                    "zip": "33461",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.61708,
                        "lon": -80.07231
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Sarnia",
                    "state": "Ontario",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 42.97866,
                        "lon": -82.40407
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Victoriaville",
                    "state": "Quebec",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 46.05007,
                        "lon": -71.96579
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                },
                {
                    "id": "D000050177",
                    "term": "Overweight"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Type 2 Diabetes Mellitus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "asFound": "Overweight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes Mellitus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}